Synlab (SYAB.VI)

Executive Summary

SYNLAB, Europe's leading laboratory diagnostic services provider, operates a critical healthcare infrastructure across 20+ countries with 2025 revenues of EUR 2.54 billion and approximately 600 million tests performed annually. The company's comprehensive diagnostic solutions support over 65% of clinical decision-making, positioning it as an essential partner to healthcare systems. Despite macroeconomic headwinds, SYNLAB's scale and geographic diversification provide resilience, with a focus on operational efficiency and margin improvement through automation and portfolio optimization. Looking ahead, SYNLAB is expected to benefit from stable demand in routine testing and potential recovery in specialty tests. The company's public listing (SYAB.VI) and strong cash flow generation support strategic investments in digitalization and M&A. Management's focus on deleveraging and shareholder returns, combined with a defensive business model, underpins a solid risk/reward profile. However, pricing pressure in mature markets and integration risks from acquisitions remain key considerations for investors.

Upcoming Catalysts (preview)

• Q2 2026Q2 2026 Earnings Release95% success
• H2 2026Acquisition of Regional Lab Chain45% success
• 2026Major Contract Win with National Health System60% success